Oxford BioMedica (LSE:OXB) Additional Paid-In Capital : £380.33 Mil(As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Additional Paid-In Capital?

Oxford BioMedica's quarterly additional paid-in capital increased from Dec. 2022 (£379.95 Mil) to Jun. 2023 (£380.25 Mil) and increased from Jun. 2023 (£380.25 Mil) to Dec. 2023 (£380.33 Mil).

Oxford BioMedica's annual additional paid-in capital increased from Dec. 2021 (£307.77 Mil) to Dec. 2022 (£379.95 Mil) and increased from Dec. 2022 (£379.95 Mil) to Dec. 2023 (£380.33 Mil).

Oxford BioMedica Additional Paid-In Capital Historical Data

The historical data trend for Oxford BioMedica's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Additional Paid-In Capital Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

222.62

258.02

307.77

379.95

380.33

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															307.77	379.95	379.95	380.25	380.33

Oxford BioMedica Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Oxford BioMedica Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines